Renalytix AI plc
("Renalytix" or the "Company")
Director / PDMR shareholding
Renalytix AI plc (AIM: RENX), a developer of artificial intelligence ("AI") enabled clinical diagnostic solutions for kidney disease, announces that it was yesterday notified that on 6 November 2018 the following PDMR undertook a transaction in the ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares"), at a price of 120 pence per Ordinary Share:
|
|
|
|
Number of Ordinary Shares bought |
Resultant Interest in Ordinary Shares |
Resultant Interest in Ordinary Shares (%) |
|
James McCullough |
Chief Executive Officer |
|
|
16,150 |
2,870,110 |
5.33 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
Name
|
James R. McCullough |
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
Chief Executive Officer |
|||
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
Renalytix AI plc |
|||
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of 0.25 pence each |
|||
|
|
||||
Identification code |
GB00BYWL4Y04 |
||||
|
|
||||
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares |
|||
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
120 pence |
16,150 |
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
n/a |
|||
|
|
||||
- Aggregated volume |
|
||||
|
|
||||
- Price |
|
||||
|
|
||||
e)
|
Date of the transaction
|
06 November 2018 |
|||
f)
|
Place of the transaction
|
London Stock Exchange |
For further information, please contact:
Renalytix AI plc |
||
James McCullough, CEO |
Via Walbrook PR or Tel: +1 646 397 3970
|
|
|
|
|
N+1 Singer (Nominated Adviser & Broker) |
Tel: 020 7496 3000 |
|
Aubrey Powell / James White / George Tzimas (Corporate Finance) |
|
|
|
|
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
Paul McManus / Lianne Cawthorne |
Mob: 07980 541 893 / 07584 391 303 |
|